Our mission is to EndBrainCancer by providing patients immediate access to specialists, advanced treatments, and comprehensive support programs. Hope Award ⬇️🧠
The End Brain Cancer Initiative (EBCI) is advocating for FDA approval of DCVax-L®, a novel treatment for Glioblastoma (GBM) brain tumors, in anticipation of submittal of the application for FDA approval by Northwest Biotherapeutics. Read Press Release: .
The End Brain Cancer Initiative (EBCI) is advocating for FDA approval of DCVax-L, a novel treatment for Glioblastoma (GBM) brain tumors, in anticipation of submittal of the application for FDA approval by
#NorthwestBio
8/29/23 - We are very happy to report that
#NWBio
has just announced their plans for submission of their Marketing Authorization Application within the next 30-45 days!
DCVax® is a platform technology that uses activated dendritic cells.
#hopeforgbm
#fightglioblastoma
#hope
Getting ready to listen to a presentation on the DC-Vax in Industry Theater 1. Come join us to hear some new information! Met up with CEO Linda Powers before the session!
#ASCO23
@NorthwestBio
@EndBrainCancer
Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) used in combination with standard-of-care treatment extended overall survival for patients with newly diagnosed glioblastoma (GBM) as well as those with recurrent disease.
Read more at
The End Brain Cancer Initiative team met at
#SNO2023
with the NW Biotherapeutics team to learn about DCVax and met with longterm DCVax patients.
Stay tuned for more!
The End Brain Cancer Initiative (EBCI) is advocating for FDA approval of DCVax-L, a novel treatment for Glioblastoma (GBM) brain tumors, in anticipation of submittal of the application for FDA approval by
#NorthwestBio
The End Brain Cancer Initiative (EBCI) is advocating for FDA approval of DCVax-L, a novel treatment for Glioblastoma (GBM) brain tumors, in anticipation of submittal of the application for FDA approval by
#NorthwestBio
The End Brain Cancer Initiative is at the 2023 SNO/ASCO Conference to increase patient access to advanced treatments and clinical trials. Visit us at Booth
#21
to meet our team!
#SNOASCO23
The End Brain Cancer Initiative (EBCI) is advocating for FDA approval of DCVax-L, a novel treatment for Glioblastoma (GBM) brain tumors, in anticipation of submittal of the application for FDA approval by
#NorthwestBio
In a groundbreaking phase III clinical trial, DCVax-L, an innovative treatment, has exhibited the potential to significantly prolong the lives of individuals grappling with both new and recurrent glioblastoma.
Learn more at
#GBM
#clinicaltrial
In a groundbreaking phase III clinical trial, DCVax-L, an innovative treatment, has exhibited the potential to significantly prolong the lives of individuals grappling with both new and recurrent glioblastoma.
Learn more at
#GBM
#clinicaltrial
Looking forward to seeing one of our favorite trailblazing neurosurgeon-scientists, Dr. Linda Liau, receive the distinguished Abhijit Guha Award!
#SNO2018
Today is
#WorldBrainTumorDay
! 🧠
Reach out to someone who was diagnosed with or has lost someone to brain cancer.
Wear a grey ribbon to promote awareness.
Learn about famous people who have survived brain tumors, such as Jimmy Carter, Scott Hamilton, & Michelle Stafford.
A new treatment for a lethal brain cancer known as glioblastoma has shown remarkable early results, new research from the Mass General Cancer Center shows.
Read more at:
#GBM
#Glioblastoma
#BrainTumor
#EBCI
#GBM
accounts for 45% of all brain cancers and affects more than 13,000 families every year. By establishing TODAY as Glioblastoma Awareness Day
#GBMDay
, we are raising awareness and shifting focus to finding treatments for this terrible disease.
#GBM
accounts for 45% of all brain cancers and affects more than 13,000 families every year. By establishing July 17th as Glioblastoma Awareness Day
#GBMDay
, we aim to raise awareness and find treatments for this terrible disease.
"The research, led by the University of Leeds, found that the synthetic chemical, named KHS101, was able to cut the energy source of tumour cells from glioblastoma, leading to the death of the cells."
Breakout session: Women In NeuroOncology: To advance the careers of women in neurooncology! This first inaugural event is bound to be epic. Thankful for all of the passionate women in this industry!
#SNO2018
#Endbraincancer
A researcher at the Oklahoma Medical Research Foundation has announced that he has discovered a new compound that can be used to fight Glioblastoma, an aggressive type of brain cancer.
Is Immunotherapy the Future of Glioblastoma Treatment? Researchers and physicians are anxiously awaiting the results of a study investigating nivolumab (Opdivo) in patients with glioblastoma.
"The EF-14 trial is the first trial in over a decade to demonstrate statistically and clinically significant extension of overall survival of patients with newly diagnosed glioblastoma regardless of patient characteristics"
"This is the opening of the GBM AGILE trial, which will allow drugs to be tested much faster and easier for GBM. New drugs can be added and underperforming drugs dropped to home in on the best treatment or combination of treatments quickly!" ~Al Musella
The results of a survey by OurBrainBank conclusively support the urgent need for education, outreach, and awareness in the brain cancer community!
Only half of respondents felt they received enough info to make educated decisions about their treatment.
#SNO2023
It's Glioblastoma Awareness Day! Create awareness, honor patients, celebrate survivors and learn how you can help! Just follow along with
#GBMDay
🧠
#EBCI
#braincancer
#braintumor
Dr John Sampson,
#DUKE
, Brain Tumor neurosurgeon, “Heterogeneity of a
#BrainTumor
is the biggest problem we have in treating GBM. Heterogeneity in GBM is different than Heterogeneity in other tumors such as breast cancer”
Quote from
#ReMissionSummit2019
#Orlando
RT
@vovo1967
: People don't notice when things change slightly: Brain Tumor-Related problems (some Often Overlooked and Underestimated). Please take this serious
#BrainTumor
👇👇👇
Each May, for the past 11 years, the EndBrainCancer Initiative, in Partnership with Novocure, has presented the HOPE award to many brain cancer patients who deeply inspire us with their courage and story.
Submit your 2024 nomination at:
May is Brain Tumor Awareness Month, and EBCI is committed to shining a light on this critical issue.
Join us in spreading the word and supporting those affected by brain tumors. Together, we can make a difference!
#BrainTumorAwarenessMonth
#GoGreyInMay
#EBCI
Dr John Sampson,
#DUKE
, Brain Tumor neurosurgeon, “Heterogeneity of a
#BrainTumor
is the biggest problem we have in treating GBM. Heterogeneity in GBM is different than Heterogeneity in other tumors such as breast cancer”
Quote from
#ReMissionSummit2019
#Orlando
"VBI-1901 is a vaccine against cytomegalovirus, or CMV. It is designed to kill glioblastoma and medulloblastoma tumor cells infected with CMV, as many are."
New research by Sussex scientists could be the first step towards developing a blood test to diagnose the most aggressive type of brain tumor, known as glioblastoma.
May 17th, 2018 we will be presenting our 2018 HOPE Award at our Annual Brains Matter Awareness, Fundraiser, & Celebration Dinner. We had some amazing nominations and have read about some amazing people.
#AdamHayden
is one of them.
The FDA draft document, "Considerations For The Design And Conduct Of Externally Controlled Trials (ECT'S) For Drugs And Biological Products" has been released for public comment! Docket
#FDA
-2022-D-2983-0019. ACT NOW!
A researcher at the Oklahoma Medical Research Foundation has announced that he has discovered a new compound that can be used to fight Glioblastoma, an aggressive type of brain cancer.
Dr. Cobbs is a brain surgeon and the director of the Ivy Center for
#BrainTumor
Treatment at Swedish. For 15 years, he’s been working to show the world that a common virus, called cytomegalovirus, fuels the highly aggressive brain tumor glioblastoma.
The huge unmet need for glioblastoma therapies reinforces the critical importance for the community to unite at the 5th Glioblastoma Drug Development Summit in Boston to collaboratively address the recurring barriers to treatment success.
Register here:
The huge unmet need for glioblastoma therapies reinforces the critical importance for the community to unite at the 5th Glioblastoma Drug Development Summit in Boston to collaboratively address the recurring barriers to treatment success.
Register here:
May is Brain Tumor Awareness Month and this year we will be bringing you more brain tumor education, news, and advocacy than ever before!
Use the
#BTAM
to follow along!🧠
#EBCI
#braincancer
"The EF-14 trial is the first trial in over a decade to demonstrate statistically and clinically significant extension of overall survival of patients with newly diagnosed glioblastoma regardless of patient characteristics"
The cyclin-dependent kinase (CDK) 4/6 inhibitors have demonstrated marked survival advantage for women with breast cancer, and now, a body of research is examining the effect of these powerful small molecules in glioblastoma.
Alarming statistic about Glioblastoma, a disease that everyone should care about!
Sources: Cleveland Clinic and Glioblastoma Research Organization
#GBM
#BrainTumor
#HealthFacts
A researcher at the Oklahoma Medical Research Foundation has announced that he has discovered a new compound that can be used to fight Glioblastoma, an aggressive type of brain cancer.
Lithium Reverses Radiation Damage After Brain Tumor Treatment. Researchers at Karolinska Institute have now shown that the drug lithium can help to reverse the damage caused long after it has occurred
The Ivy Brain Tumor Center announces promising results from a Phase 0/2 trial of niraparib in patients with newly diagnosed glioblastoma with unmethylated MGMT.
Updated data from this collaborative study will be presented in two oral presentations at
#SNO2023
.
National Conference by
@theABTA
is taking place on 9/10 - 9/11 virtually this year.
Register now to learn the latest advancements in brain tumor care from medical experts. 🧠
#braintumor
#braincancer
Society for NeuroOncology - Nov. 15th - 18th: 23rd Annual Meeting & Education Day! in New Orleans. Looking forward to learning from top Neuros from around the world, reporting about new technologies, clinical trials, offering our resources and expanding awareness!
#SNO2018
A researcher at the Oklahoma Medical Research Foundation has announced that he has discovered a new compound that can be used to fight Glioblastoma, an aggressive type of brain cancer.
"The research, led by the University of Leeds, found that the synthetic chemical, named KHS101, was able to cut the energy source of tumour cells from glioblastoma, leading to the death of the cells."
Roughly 66 people are diagnosed EVERY DAY with a primary brain tumor. We are here to tell you that the Journey Begins With Hope. We want to inspire you to both FIGHT and
#HOPE
. We are here to help.
#EndBrainCancer
#EBCI
Good News! E-BEAM Services has donated to the American Brain Tumor Association (ABTA). Sam Strotman, President & COO of E-BEAM, stated, “In honor of GT Medical Technologies, Inc. for all their incredible work and efforts towards improving the lives of patients with brain tumors.”
We are grateful to
#SNO2018
for working so hard to fulfill its mission to advance neuro-oncology research and education! Looking forward to planning our day, gleaning from some of the best in the field and furthering our goal to provide patient services!
#endbraincancer
Very informative presentation with Dr. Kirson the Chief Science Officer at
#Novocure
. Promising stats and exciting developments in the fight against
#BrainCancer
!
Great welcome by David Arons, CEO of
#natlbraintumorsociety
at the
#HeadtotheHill
even in Washington DC. Pat Jones, on our Scientific Advisory Board will be meeting with Congress to fight for brain tumor patients & their families.
"What makes GBM so uniquely resistant to standard cancer treatments? The NINDS and NCI hope to answer this by funding and conducting innovative, rigorous research to help us better understand disease mechanisms and develop more effective treatments."